Clinical Trials
9 trialsNCT06787612 2026-05-20
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Regeneron Pharmaceuticals
Phase 2 Recruiting
NCT06014528 2025-04-30
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
InxMed (Shanghai) Co., Ltd.
Phase 2 Recruiting
NCT02272790 2023-10-03
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
AstraZeneca
Phase 2 Completed
NCT05201001 2023-09-11
APX005M
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Withdrawn
NCT03161132 2023-01-27
ROLANDO
Grupo Español de Investigación en Cáncer de Ovario
Phase 2 Completed
NCT04348032 2022-03-31
APPROVE
ChineseAMS
Phase 2 Unknown
NCT04887961 2021-08-09
MITO36
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Unknown
NCT04983550 2021-07-30
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT01991210 2017-08-21
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
Genentech, Inc.
Phase 2 Terminated